Literature DB >> 16635421

Neuromyelitis optica.

D M Wingerchuk1.   

Abstract

Neuromyelitis optica (NMO), otherwise known as Devic's disease, is an idiopathic, severe, inflammatory disorder that preferentially affects the optic nerves and spinal cord. Clinical, laboratory and immunopathological evidence suggests that NMO is a humorally mediated disease distinct from MS. A spinal cord lesion extending contiguously over three or more vertebral segments is characteristic of NMO and, in combination with a cranial magnetic resonance imaging scan that does not meet radiological criteria for MS, is over 94% sensitive and 96% specific for NMO diagnosis. The serum autoantibody marker, neuromyelitis optica-immunoglobulin G (NMO-IgG), appears specific for NMO and suggests that the disease spectrum includes cases of recurrent longitudinally extensive transverse myelitis and Japanese opticospinal MS. Its target antigen is the water channel aquaporin-4, suggesting that NMO may represent a novel autoimmune channelopathy. Relapsing NMO has a poor prognosis; therapy, typically with immunosuppression, is necessary as early as possible in the disease course to prevent attack-related disability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16635421

Source DB:  PubMed          Journal:  Int MS J        ISSN: 1352-8963


  15 in total

1.  Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports.

Authors:  Silvia R Delgado; William A Sheremata; Andrew D Brown; Micheline McCarthy
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  Spatial normalization and regional assessment of cord atrophy: voxel-based analysis of cervical cord 3D T1-weighted images.

Authors:  P Valsasina; M A Horsfield; M A Rocca; M Absinta; G Comi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-07       Impact factor: 3.825

3.  A mighty mouse: building a better model of multiple sclerosis.

Authors:  Richard M Ransohoff
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

4.  Bilateral Internuclear Ophthalmoplegia in a Patient with Devic's Neuromyelitis Optica.

Authors:  E Garcia-Martin; I Pinilla; V Pueyo; L Gil; J Martinez-Morales; J Fernandez
Journal:  Case Rep Neurol       Date:  2010-11-12

5.  Identification of tissue-specific cell death using methylation patterns of circulating DNA.

Authors:  Roni Lehmann-Werman; Daniel Neiman; Hai Zemmour; Joshua Moss; Judith Magenheim; Adi Vaknin-Dembinsky; Sten Rubertsson; Bengt Nellgård; Kaj Blennow; Henrik Zetterberg; Kirsty Spalding; Michael J Haller; Clive H Wasserfall; Desmond A Schatz; Carla J Greenbaum; Craig Dorrell; Markus Grompe; Aviad Zick; Ayala Hubert; Myriam Maoz; Volker Fendrich; Detlef K Bartsch; Talia Golan; Shmuel A Ben Sasson; Gideon Zamir; Aharon Razin; Howard Cedar; A M James Shapiro; Benjamin Glaser; Ruth Shemer; Yuval Dor
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

6.  Pelvic pain as an unusual first presentation of a demyelinating disease.

Authors:  A Lukas Loschner; John E Snyder
Journal:  J Gen Intern Med       Date:  2008-09-04       Impact factor: 5.128

7.  Neuromyelitis Optica with NMO-IgG/Anti-AQP4 Antibody Positive: First Case Reported from Uttarakhand India.

Authors:  Manish Mittal; Garima Mittal
Journal:  J Clin Diagn Res       Date:  2014-07-20

Review 8.  Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics.

Authors:  Laura Cacciaguerra; Paola Tortorella; Maria A Rocca; Massimo Filippi
Journal:  Neurotherapeutics       Date:  2021-04-28       Impact factor: 6.088

9.  Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics.

Authors:  Iris Grossman; Ariel Miller
Journal:  EPMA J       Date:  2010-06-09       Impact factor: 6.543

10.  Neuromyelitis optica with CSF examination mimicking bacterial meningomyelitis.

Authors:  Dragan Lepur; Vjerislav Peterković; Nevija Kalabrić-Lepur
Journal:  Neurol Sci       Date:  2009-01-15       Impact factor: 3.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.